We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+15.26%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.36B
AUM Growth
+$269M
Cap. Flow
-$71.3M
Cap. Flow %
-2.12%
Top 10 Hldgs %
68.61%
Holding
29
New
1
Increased
9
Reduced
13
Closed
2

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$43.6M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$33.6M
3
CEMP
Cempra, Inc.
CEMP
+$13.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.53M
5
TSRO
TESARO, Inc.
TSRO
+$7.07M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$89.4M
2
INCY icon
Incyte
INCY
+$21.5M
3
CELG
Celgene Corp
CELG
+$19.1M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$16.8M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 82.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
26
Innoviva
INVA
$1.48B
$13.1M 0.39%
831,594
-211,650
-20% -$3.2M
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$12.6M 0.38%
1,279,340
+200,000
+19% +$2.5M
PCYC
28
DELISTED
PHARMACYCLICS INC
PCYC
– –
-731,542
Closed -$89.4M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2015 Portfolio in Review

As of Q1 2015, BB Biotech held 29 positions worth $3.36B, up 8.7% from $3.09B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

BB Biotech's Q1 2015 filing shows 1 new, 9 increased, 13 reduced and 2 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 155,000 shares worth $43.7M. The largest sale was PHARMACYCLICS INC, an estimated $89.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier.

  • BB Biotech's largest Q1 2015 buy was Intercept Pharmaceuticals, Inc.: 155,000 shares worth $43.7M.
  • BB Biotech added most to Radius Health, Inc. in Q1 2015, an estimated $43.6M increase.
  • BB Biotech's biggest Q1 2015 reduction was Incyte, cutting an estimated $21.5M.
  • BB Biotech fully exited PHARMACYCLICS INC in Q1 2015, selling an estimated $89.4M.
  • BB Biotech's ten largest holdings make up 69% of its $3.36B portfolio in Q1 2015.
  • BB Biotech opened 1 new position and closed 2 in Q1 2015.
  • BB Biotech's portfolio value rose 8.7% quarter-over-quarter to $3.36B.

Based on BB Biotech's 13F filing for Q1 2015, filed 14 May 2015.